Cargando…
Nanotechnology for virus treatment
The continued emergence of novel viruses poses a significant threat to global health. Uncontrolled outbreaks can result in pandemics that have the potential to overburden our healthcare and economic systems. While vaccination is a conventional modality that can be employed to promote herd immunity,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836394/ https://www.ncbi.nlm.nih.gov/pubmed/33519948 http://dx.doi.org/10.1016/j.nantod.2020.101031 |
_version_ | 1783642739701710848 |
---|---|
author | Zhou, Jiarong Krishnan, Nishta Jiang, Yao Fang, Ronnie H. Zhang, Liangfang |
author_facet | Zhou, Jiarong Krishnan, Nishta Jiang, Yao Fang, Ronnie H. Zhang, Liangfang |
author_sort | Zhou, Jiarong |
collection | PubMed |
description | The continued emergence of novel viruses poses a significant threat to global health. Uncontrolled outbreaks can result in pandemics that have the potential to overburden our healthcare and economic systems. While vaccination is a conventional modality that can be employed to promote herd immunity, antiviral vaccines can only be applied prophylactically and do little to help patients who have already contracted viral infections. During the early stages of a disease outbreak when vaccines are unavailable, therapeutic antiviral drugs can be used as a stopgap solution. However, these treatments do not always work against emerging viral strains and can be accompanied by adverse effects that sometimes outweigh the benefits. Nanotechnology has the potential to overcome many of the challenges facing current antiviral therapies. For example, nanodelivery vehicles can be employed to drastically improve the pharmacokinetic profile of antiviral drugs while reducing their systemic toxicity. Other unique nanomaterials can be leveraged for their virucidal or virus-neutralizing properties. In this review, we discuss recent developments in antiviral nanotherapeutics and provide a perspective on the application of nanotechnology to the SARS-CoV-2 outbreak and future virus pandemics. |
format | Online Article Text |
id | pubmed-7836394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78363942021-01-26 Nanotechnology for virus treatment Zhou, Jiarong Krishnan, Nishta Jiang, Yao Fang, Ronnie H. Zhang, Liangfang Nano Today Article The continued emergence of novel viruses poses a significant threat to global health. Uncontrolled outbreaks can result in pandemics that have the potential to overburden our healthcare and economic systems. While vaccination is a conventional modality that can be employed to promote herd immunity, antiviral vaccines can only be applied prophylactically and do little to help patients who have already contracted viral infections. During the early stages of a disease outbreak when vaccines are unavailable, therapeutic antiviral drugs can be used as a stopgap solution. However, these treatments do not always work against emerging viral strains and can be accompanied by adverse effects that sometimes outweigh the benefits. Nanotechnology has the potential to overcome many of the challenges facing current antiviral therapies. For example, nanodelivery vehicles can be employed to drastically improve the pharmacokinetic profile of antiviral drugs while reducing their systemic toxicity. Other unique nanomaterials can be leveraged for their virucidal or virus-neutralizing properties. In this review, we discuss recent developments in antiviral nanotherapeutics and provide a perspective on the application of nanotechnology to the SARS-CoV-2 outbreak and future virus pandemics. Elsevier Ltd. 2021-02 2020-12-01 /pmc/articles/PMC7836394/ /pubmed/33519948 http://dx.doi.org/10.1016/j.nantod.2020.101031 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Zhou, Jiarong Krishnan, Nishta Jiang, Yao Fang, Ronnie H. Zhang, Liangfang Nanotechnology for virus treatment |
title | Nanotechnology for virus treatment |
title_full | Nanotechnology for virus treatment |
title_fullStr | Nanotechnology for virus treatment |
title_full_unstemmed | Nanotechnology for virus treatment |
title_short | Nanotechnology for virus treatment |
title_sort | nanotechnology for virus treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836394/ https://www.ncbi.nlm.nih.gov/pubmed/33519948 http://dx.doi.org/10.1016/j.nantod.2020.101031 |
work_keys_str_mv | AT zhoujiarong nanotechnologyforvirustreatment AT krishnannishta nanotechnologyforvirustreatment AT jiangyao nanotechnologyforvirustreatment AT fangronnieh nanotechnologyforvirustreatment AT zhangliangfang nanotechnologyforvirustreatment |